Emerging Threats in Urinary Tract Infections: Revealing Antimicrobial Susceptibility and Resistance trends of Developed Extended-Spectrum Beta-Lactamases Producing E. coli
DOI:
https://doi.org/10.65035/yd9adv06Keywords:
Antimicrobial Susceptibility, Beta- Lactamases, Double Disc Synergy Test, E. coli, Urinary Tract InfectionsAbstract
Background: The main aim of the study was to identify the development of antimicrobial susceptibility and resistance in Extended-Spectrum Beta-Lactamase (ESBL) producing E. coli. that cause UTI and to determine suitable antibiotic choices in the said organisms.
Methodology: It was a Cross-sectional retrospective study, where 200 clinical uropathogenic E. coli isolates were picked and assessed antimicrobial resistance by the Kirby buyer method and confirmation was performed using a double disc synergy test to detect ESBN producers.
Findings: The paper illustrates that females (82%), adults (50%), have a high risk of developing such infections because of several changes in the anatomy and behaviours. Imipenem, amikacin, Fosfomycin and tazobactam/piperacillin possess 98.5, 91.0, 84.5 and 86 patterns of sensitivity to E. coli isolates collected and thus can be used as a choice of treatment against UTIs caused by E. coli 46/65 65 E. coli isolates were found to be multidrug-resistant by initial screening of antimicrobial susceptibility test and therefore confirmed to be 60.7.
Conclusion: It was ascertained that although the E. coli has since developed resistance to many of the medicines yet there are a few antibiotics that can be considered when writing the prescription. These infections are more prevalent among women and adults, and they should be educated adequately to avoid them.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Noor us Saba Mansoor, Huma Dilshad, Javeria Sheikh, Anum Sattar, Shehla Rehmat, Sadia Mudassar (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in the Journal of Medical & Health Sciences Review (JMHSR) remain the copyright of their respective authors. JMHSR publishes its content under the Creative Commons Attribution‑NonCommercial 4.0 International License (CC BY‑NC 4.0), which allows readers to freely share, copy, adapt, and build upon the work for non‑commercial purposes, provided proper credit is given to both the authors and the journal.



